HighTower Advisors’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

HighTower Advisors’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,350	Closed	-$1.78M	–	1882
2016 Q2	$1.78M	Buy	5,350 +2,478	+86%	+$783K	0.02%	660
2016 Q1	$1M	Buy	+2,872	New	+$999K	﹤0.01%	1036
2015 Q4	–	Sell	-1,044	Closed	-$323K	–	2052
2015 Q3	$323K	Buy	+1,044	New	+$246K	﹤0.01%	1420
2014 Q4	–	Sell	-1,174	Closed	-$565K	–	1590
2014 Q3	$565K	Buy	+1,174	New	+$625K	0.01%	982

Other funds holding BIS

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

USGIU

U.S. Global Investors (USGI) San Antonio, Texas $1.04B AUM 73.31% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Howe & Rusling Rochester, New York $1.53B AUM 21.45% 1-Year Est. Return

HighTower Advisors's BIS Position: Q3 2016 in Review

HighTower Advisors sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2016, closing a stake of 5,350 shares — an estimated $1.78M sold.

HighTower Advisors first reported a position in BIS in Q3 2014 and held it in 4 quarters. The position peaked at $1.78M in Q2 2016. 10 funds tracked by Wall St. Rank hold BIS as of Q3 2016.

HighTower Advisors reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2016 after selling out during the quarter.
HighTower Advisors sold 5,350 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2016, an estimated $1.78M.
HighTower Advisors first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2014 and held it in 4 quarters.
HighTower Advisors's ProShares UltraShort NASDAQ Biotechnology position peaked at $1.78M in Q2 2016.
10 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2016.

Based on HighTower Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.